Tesaglitazar

Tesaglitazar
	File:Tesaglitazar.png
Systematic (IUPAC) name
	(2S)-2-Ethoxy-3-[4-[2-(4-methylsulfonyloxyphenyl)ethoxy]phenyl]propanoic acid
Identifiers
CAS Number	251565-85-2
ATC code	none
PubChem	CID 208901
Chemical data
Formula	C20H24O7S
Molar mass	408.46[[Script error: No such module "String".]]
	Script error: No such module "collapsible list".

Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Tesaglitazar is a peroxisome proliferator-activated receptor agonist with affinity to PPARα and PPARγ, proposed for type 2 diabetes.^[1]

The drug had completed several phase III clinical trials,^[2] however in May, 2006 AstraZeneca announced that it had discontinued further development.^[3]

References

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />

45px	This drug article relating to the gastrointestinal system is a stub. You can help ssf by expanding it. v d e

↑ Wilding JP, Gause-Nilsson I, Persson A (2007). "Tesaglitazar, as add-on therapy to sulphonylurea, dose-dependently improves glucose and lipid abnormalities in patients with type 2 diabetes". Diab Vasc Dis Res. 4 (3): 194–203. doi:10.3132/dvdr.2007.040. PMID 17907109.
↑ "GALIDA (tesaglitazar) Clinical Trial Report Summaries". AstraZeneca. Retrieved 2008-03-17.
↑ "AstraZeneca Discontinues Development of GALIDA (tesaglitazar)". AstraZeneca. 2006-05-04. Retrieved 2008-03-17.